Sign In
Buy MNLO
$0.555
+0 (+0%)
At Close: Aug 17, 2022
Bank of New York Mellon Corp Acquires 105,868 Shares of Menlo Therapeutics Inc (NASDAQ:MNLO)
04:26am, Monday, 22'nd Jun 2020
Bank of New York Mellon Corp raised its holdings in Menlo Therapeutics Inc (NASDAQ:MNLO) by 153.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. T
Russell Investments Group Ltd. Cuts Stock Holdings in Menlo Therapeutics Inc (NASDAQ:MNLO)
07:04am, Wednesday, 17'th Jun 2020
Russell Investments Group Ltd. reduced its position in shares of Menlo Therapeutics Inc (NASDAQ:MNLO) by 49.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchang
Menlo Therapeutics Inc.'s (NASDAQ:MNLO) Profit Outlook
11:34am, Thursday, 11'th Jun 2020
Menlo Therapeutics Inc.'s (NASDAQ:MNLO): Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and...
BlackRock Inc. Raises Stock Holdings in Menlo Therapeutics Inc (NASDAQ:MNLO)
04:10am, Wednesday, 10'th Jun 2020
BlackRock Inc. raised its position in shares of Menlo Therapeutics Inc (NASDAQ:MNLO) by 210.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commissi
Menlo Therapeutics: Strong Amzeeq Launch, Recent Zilxi Approval And Positive FCD105 Results Point To Growth Ahead (NASDAQ:MNLO)
08:10pm, Monday, 08'th Jun 2020
MNLO is launching several best-in-class dermatology products, yet shares still do not reflect the progress. Lead product, Amzeeq® has come out strong beating an
Why Menlo Therapeutics Stock Sank Today
07:41pm, Friday, 05'th Jun 2020
The decline came after the company announced the pricing of a stock offering Friday morning. The number of shares being offered represents nearly 20% of the total number of outstanding shares. Stock
Menlo Therapeutics Announces Pricing of Offering of Common Stock
11:00am, Friday, 05'th Jun 2020
Menlo Therapeutics Inc. (“Menlo”) (MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced
The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid
12:00am, Friday, 05'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 4)
Biohaven Pharmaceutical...
Menlo Therapeutics Announces Proposed Offering of Common Stock
08:01pm, Thursday, 04'th Jun 2020
Menlo Therapeutics Inc. (“Menlo”) (MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced
This Analyst Thinks Menlo (MNLO) Stock Is Poised for Growth
04:40pm, Tuesday, 02'nd Jun 2020
2020 has been kind to small-cap biotechs. Some have spiked upwards dramatically this year, mostly on the hope of finding solutions to COVID-19, be it a treatment or vaccine. Those who haven’t gotten
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
12:00pm, Tuesday, 02'nd Jun 2020
Study FX2016-40 enrolled 447 patients in the United States who were randomized to either FCD105 foam, 3% minocycline foam, 0.3% adapalene foam, or vehicle foam. The Company has begun preparations to
The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight
12:00am, Saturday, 30'th May 2020
Biotech stocks could not sustain the uptrend in the holiday-shortened week, even as traders digested COVID-19-related news flow, clinical readouts, ASCO presentations and a few...
Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatol
Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%
12:43pm, Wednesday, 27'th May 2020
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Menlo Therapeutics Announces Covered Status for AMZEEQ® (minocycline) topical foam, 4%, on Additional Commercial Formulary
12:00pm, Wednesday, 27'th May 2020
Coverage Effective Immediately on One of the Largest Payor Networks in the U.S. AMZEEQ® is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to.
